Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9Y5K5
UPID:
UCHL5_HUMAN
Alternative names:
Ubiquitin C-terminal hydrolase UCH37; Ubiquitin thioesterase L5
Alternative UPACC:
Q9Y5K5; Q5LJA6; Q5LJA7; Q8TBS4; Q96BJ9; Q9H1W5; Q9P0I3; Q9UQN2
Background:
Ubiquitin carboxyl-terminal hydrolase isozyme L5, also known as Ubiquitin C-terminal hydrolase UCH37 and Ubiquitin thioesterase L5, plays a crucial role in protein degradation. It specifically cleaves 'Lys-48'-linked polyubiquitin chains and is associated with the 19S regulatory subunit of the 26S proteasome. Additionally, it is a putative regulatory component of the INO80 complex but is activated by a transient interaction with the proteasome via ADRM1.
Therapeutic significance:
Understanding the role of Ubiquitin carboxyl-terminal hydrolase isozyme L5 could open doors to potential therapeutic strategies.